Protective effects of Lactobacillus plantarum against epithelial barrier dysfunction of human colon cell line NCM460

World Journal of Gastroenterology

Volumn 16, Issue 45, 2010, Pages 5759-5765

  Liu, Zhi Hua ^a   Shen, Tong Yi ^b   Zhang, Peng ^a   Ma, Yan Lei ^a   Moyer, Mary Pat ^c   Qin, Huan Long ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^c INCELL Corporation ^*  (United States)

Author keywords

Intestinal barrier; Lactobacillus plantarum; NCM460; Tight junction

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; DRUG EFFECT; ELECTRIC RESISTANCE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; LACTOBACILLUS PLANTARUM; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TIGHT JUNCTION; WESTERN BLOTTING;

EID: 78649899823     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i45.5759     Document Type: Article

References (34)

1. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920
2. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol 2010; 16: 403-410
3. Turroni S, Vitali B, Candela M, Gionchetti P, Rizzello F, Campieri M, Brigidi P. Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. World J Gastroenterol 2010; 16: 30-41
4. Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007; 56: 1240-1247
5. Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut 2007; 56: 610-612
6. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by tolllike receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241
7. Fiocchi C. One commensal bacterial molecule--all we need for health? N Engl J Med 2005; 353: 2078-2080
8. Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on host-pathogen interactions within the intestine: gutderived sepsis redefined. Crit Care Med 2003; 31: 598-607
9. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633
10. Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Ma M, Churchill T, Madsen K. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007; 46: 841-850
11. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol 2010; 16: 69-75
12. Matsuzaki T, Takagi A, Ikemura H, Matsuguchi T, Yokokura T. Intestinal microflora: probiotics and autoimmunity. J Nutr 2007; 137: 798S-802S
13. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591
14. Makharia GK, Sood A, Midha V, Ahuja V, Singal DK, Arora R, Sood S, Goswami P, De Simone C, Sahu AR, Tandon RK. A randomized, double-blind, placebo-controlled trial of a probiotic preparation, Vsl#3, for the treatment of mild to moderate active ulcerative colitis. Gastroenterology 2008; 134 Suppl 1: A-99
15. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443
16. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639
17. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15: 300-310
18. García-Lafuente A, Antolín M, Guarner F, Crespo E, Malagelada JR. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut 2001; 48: 503-507
19. Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 2007; 56: 1522-1528
20. Zhang M, Wang XQ, Zhou YK, Ma YL, Shen TY, Chen HQ, Chu ZX, Qin HL. Effects of oral Lactobacillus plantarum on hepatocyte tight junction structure and function in rats with obstructive jaundice. Mol Biol Rep 2010; 37: 2989-2999
21. Liu Z, Zhang P, Ma Y, Chen H, Zhou Y, Zhang M, Chu Z, Qin H. Lactobacillus plantarum prevents the development of colitis in IL-10-deficient mouse by reducing the intestinal permeability. Mol Biol Rep 2010; Epub ahead of print
22. Qin H, Zhang Z, Hang X, Jiang Y. L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells. BMC Microbiol 2009; 9: 63
23. Chu ZX, Chen HQ, Ma YL, Zhou YK, Zhang M, Zhang P, Qin HL. Lactobacillus plantarum prevents the upregulation of adhesion molecule expression in an experimental colitis model. Dig Dis Sci 2010; 55: 2505-2513
24. Qin HL, Zheng JJ, Tong DN, Chen WX, Fan XB, Hang XM, Jiang YQ. Effect of Lactobacillus plantarum enteral feeding on the gut permeability and septic complications in the patients with acute pancreatitis. Eur J Clin Nutr 2008; 62: 923-930
25. Moss AC, Anton P, Savidge T, Newman P, Cheifetz AS, Gay J, Paraschos S, Winter MW, Moyer MP, Karalis K, Kokkotou E, Pothoulakis C. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut 2007; 56: 1210-1217
26. Kim H, Kokkotou E, Na X, Rhee SH, Moyer MP, Pothoulakis C, Lamont JT. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 2005; 129: 1875-1888
27. Koon HW, Zhao D, Zhan Y, Moyer MP, Pothoulakis C. Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc Natl Acad Sci USA 2007; 104: 2013-2018
28. Lelievre V, Hu Z, Byun JY, Ioffe Y, Waschek JA. Fibroblast growth factor-2 converts PACAP growth action on embryonic hindbrain precursors from stimulation to inhibition. J Neurosci Res 2002; 67: 566-573
29. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16: 658-672
30. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun 2008; 76: 1340-1348
31. Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology 2006; 130: 731-746
32. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007; 104: 7617-7621
33. Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157: H7 infection in mice. FEMS Immunol Med Microbiol 2004; 41: 219-226
34. Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PS, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127: H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 2005; 73: 5183-5188